Standard

Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus. / Matveev, A. L.; Khlusevich, Ya A.; Baykov, I. K. et al.

In: Вавиловский журнал генетики и селекции, Vol. 21, No. 8, 01.01.2017, p. 993-1000.

Research output: Contribution to journalArticlepeer-review

Harvard

Matveev, AL, Khlusevich, YA, Baykov, IK, Babkin, IV, Goncharova, EP, Morozova, VV & Tikunova, NV 2017, 'Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus', Вавиловский журнал генетики и селекции, vol. 21, no. 8, pp. 993-1000. https://doi.org/10.18699/VJ17.324

APA

Matveev, A. L., Khlusevich, Y. A., Baykov, I. K., Babkin, I. V., Goncharova, E. P., Morozova, V. V., & Tikunova, N. V. (2017). Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus. Вавиловский журнал генетики и селекции, 21(8), 993-1000. https://doi.org/10.18699/VJ17.324

Vancouver

Matveev AL, Khlusevich YA, Baykov IK, Babkin IV, Goncharova EP, Morozova VV et al. Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus. Вавиловский журнал генетики и селекции. 2017 Jan 1;21(8):993-1000. doi: 10.18699/VJ17.324

Author

Matveev, A. L. ; Khlusevich, Ya A. ; Baykov, I. K. et al. / Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus. In: Вавиловский журнал генетики и селекции. 2017 ; Vol. 21, No. 8. pp. 993-1000.

BibTeX

@article{df755495e3bd452d839384aa5e6debde,
title = "Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus",
abstract = "Fully-human antibodies have a great therapeutic importance; however, the development of stable strains providing a high level of production of full-size antibodies is a challenging task, as antibody molecules contain two types of polypeptide chains. To develop the producing strain, random integration of the plasmid containing the gene encoding the target protein into the genome of the host cells is commonly used. The aim of this study was the development of an original expression system, using gene targeting to integrate the gene encoding the fully-human antibody into the transcriptionally active region of the genome of eukaryotic suspension cells CHO-S. To develop a stable strain, the cassette vector plasmid pCDNA5/FRTDHFR- CH-CL containing the site of homologous recombination and the genes encoding heavy and light chains of the fully human antibody of the IgG1/kappa class was constructed at the first step. Notably, DNA of the plasmid pCDNA5/FRT-DHFR-CH-CL was organized in such a way that the restriction sites for rapid cloning of DNA fragments encoding the variable domains of heavy and light chains were inserted upstream of the sequences encoding constant domains of the heavy and light chains of the antibody. Secondly, DNA fragments encoding the variable domains of the heavy and light chains of antibody against orthopoxvirus protein p35 were inserted into the pCDNA5/FRT-DHFRCH- CL cassette plasmid. Then, CHO-S/FRT cells, which contain the FRT-site for homologous recombination and are able to produce green fluorescence protein GFP, were transfected with the constructed plasmid. After the insertion of the target genes into the FRT-site, GFP production was supposed to stop. Using this selection system, a stable clone producing target antibody fh8E was selected with the level of production of about 100 μg/ml. The binding affinity of purified antibody fh8E with the targeted protein, measured by surface plasmon resonance, was 12 nM. In addition, antibody fh8E demonstrated anti-vaccinia virus activity in the plaque reduction neutralization test in vitro.",
keywords = "CHO cells, Ectromelia virus, Fully human antibody, Genomic amplification, Plasmid, Producing strain",
author = "Matveev, {A. L.} and Khlusevich, {Ya A.} and Baykov, {I. K.} and Babkin, {I. V.} and Goncharova, {E. P.} and Morozova, {V. V.} and Tikunova, {N. V.}",
year = "2017",
month = jan,
day = "1",
doi = "10.18699/VJ17.324",
language = "English",
volume = "21",
pages = "993--1000",
journal = "Вавиловский журнал генетики и селекции",
issn = "2500-0462",
publisher = "Institute of Cytology and Genetics of Siberian Branch of the Russian Academy of Sciences",
number = "8",

}

RIS

TY - JOUR

T1 - Development of a stable eukaryotic strain producing fully human monoclonal antibody on the basis of the human antibody against ectromelia virus

AU - Matveev, A. L.

AU - Khlusevich, Ya A.

AU - Baykov, I. K.

AU - Babkin, I. V.

AU - Goncharova, E. P.

AU - Morozova, V. V.

AU - Tikunova, N. V.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Fully-human antibodies have a great therapeutic importance; however, the development of stable strains providing a high level of production of full-size antibodies is a challenging task, as antibody molecules contain two types of polypeptide chains. To develop the producing strain, random integration of the plasmid containing the gene encoding the target protein into the genome of the host cells is commonly used. The aim of this study was the development of an original expression system, using gene targeting to integrate the gene encoding the fully-human antibody into the transcriptionally active region of the genome of eukaryotic suspension cells CHO-S. To develop a stable strain, the cassette vector plasmid pCDNA5/FRTDHFR- CH-CL containing the site of homologous recombination and the genes encoding heavy and light chains of the fully human antibody of the IgG1/kappa class was constructed at the first step. Notably, DNA of the plasmid pCDNA5/FRT-DHFR-CH-CL was organized in such a way that the restriction sites for rapid cloning of DNA fragments encoding the variable domains of heavy and light chains were inserted upstream of the sequences encoding constant domains of the heavy and light chains of the antibody. Secondly, DNA fragments encoding the variable domains of the heavy and light chains of antibody against orthopoxvirus protein p35 were inserted into the pCDNA5/FRT-DHFRCH- CL cassette plasmid. Then, CHO-S/FRT cells, which contain the FRT-site for homologous recombination and are able to produce green fluorescence protein GFP, were transfected with the constructed plasmid. After the insertion of the target genes into the FRT-site, GFP production was supposed to stop. Using this selection system, a stable clone producing target antibody fh8E was selected with the level of production of about 100 μg/ml. The binding affinity of purified antibody fh8E with the targeted protein, measured by surface plasmon resonance, was 12 nM. In addition, antibody fh8E demonstrated anti-vaccinia virus activity in the plaque reduction neutralization test in vitro.

AB - Fully-human antibodies have a great therapeutic importance; however, the development of stable strains providing a high level of production of full-size antibodies is a challenging task, as antibody molecules contain two types of polypeptide chains. To develop the producing strain, random integration of the plasmid containing the gene encoding the target protein into the genome of the host cells is commonly used. The aim of this study was the development of an original expression system, using gene targeting to integrate the gene encoding the fully-human antibody into the transcriptionally active region of the genome of eukaryotic suspension cells CHO-S. To develop a stable strain, the cassette vector plasmid pCDNA5/FRTDHFR- CH-CL containing the site of homologous recombination and the genes encoding heavy and light chains of the fully human antibody of the IgG1/kappa class was constructed at the first step. Notably, DNA of the plasmid pCDNA5/FRT-DHFR-CH-CL was organized in such a way that the restriction sites for rapid cloning of DNA fragments encoding the variable domains of heavy and light chains were inserted upstream of the sequences encoding constant domains of the heavy and light chains of the antibody. Secondly, DNA fragments encoding the variable domains of the heavy and light chains of antibody against orthopoxvirus protein p35 were inserted into the pCDNA5/FRT-DHFRCH- CL cassette plasmid. Then, CHO-S/FRT cells, which contain the FRT-site for homologous recombination and are able to produce green fluorescence protein GFP, were transfected with the constructed plasmid. After the insertion of the target genes into the FRT-site, GFP production was supposed to stop. Using this selection system, a stable clone producing target antibody fh8E was selected with the level of production of about 100 μg/ml. The binding affinity of purified antibody fh8E with the targeted protein, measured by surface plasmon resonance, was 12 nM. In addition, antibody fh8E demonstrated anti-vaccinia virus activity in the plaque reduction neutralization test in vitro.

KW - CHO cells

KW - Ectromelia virus

KW - Fully human antibody

KW - Genomic amplification

KW - Plasmid

KW - Producing strain

UR - http://www.scopus.com/inward/record.url?scp=85040969188&partnerID=8YFLogxK

U2 - 10.18699/VJ17.324

DO - 10.18699/VJ17.324

M3 - Article

AN - SCOPUS:85040969188

VL - 21

SP - 993

EP - 1000

JO - Вавиловский журнал генетики и селекции

JF - Вавиловский журнал генетики и селекции

SN - 2500-0462

IS - 8

ER -

ID: 10455527